Form 4: Centene Director Christopher Coughlin Receives Stock Grant

Centene Corporation Director Christopher J. Coughlin was granted 3,992 restricted stock units as part of his compensation.

Summary

• Director Christopher J. Coughlin acquired 3,992 shares of Centene Corporation (CNC) common stock.
• The shares were granted as restricted stock units (RSUs) with a price of $0.
• Following this transaction, Mr. Coughlin's direct beneficial ownership increased to 18,148.926 shares.
• Mr. Coughlin maintains an additional indirect holding of 30,054 shares through a Grantor Retained Annuity Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.
• The director maintains a significant total stake in the company, totaling over 48,000 shares combined.

Negatives

• None identified.

Risks

• The value of the equity grant is subject to market volatility and the future performance of Centene Corporation stock.

Future Outlook

The restricted stock units are scheduled to vest in full on May 12, 2027, or on the date of the next annual meeting of stockholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the managed healthcare sector to ensure long-term alignment with shareholder interests.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with industry practices at peers such as UnitedHealth Group and Elevance Health.

Stakeholder Impact

• Shareholders benefit from the continued alignment of director incentives with company performance.

Next Steps

• Vesting of the 3,992 restricted stock units on May 12, 2027.

Key Dates

Keywords

Centene, CNC, Director, Insider Trading, Form 4, Equity Compensation